Altimmune, Inc. (ALT)

NASDAQ: ALT · IEX Real-Time Price · USD
7.11
-0.41 (-5.45%)
Apr 17, 2024, 3:44 PM EDT - Market open
-5.45%
Market Cap 504.42M
Revenue (ttm) 426,000
Net Income (ttm) -88.45M
Shares Out 70.90M
EPS (ttm) -1.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,822,613
Open 7.65
Previous Close 7.52
Day's Range 7.06 - 7.65
52-Week Range 2.09 - 14.84
Beta 0.06
Analysts Strong Buy
Price Target 15.00 (+110.97%)
Earnings Date May 9, 2024

About ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed ... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Vipin K. Garg Ph.D.
Employees 59
Stock Exchange NASDAQ
Ticker Symbol ALT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ALT stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 110.97% from the latest price.

Price Target
$15.0
(110.97% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Altimmune says weight loss drug minimized muscle loss in trial results that may set it apart

The results are a sign that Altimmune can address an area of concern around weight loss drugs, which is that they shrink critical muscle mass.

21 days ago - CNBC

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associat...

21 days ago - GlobeNewsWire

Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024

GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 20...

4 weeks ago - GlobeNewsWire

ROSEN, A LONGSTANDING LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

NEW YORK , March 5, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune, Inc. (NASD...

6 weeks ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT

NEW YORK , March 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT).  Such investors are advised to co...

6 weeks ago - PRNewsWire

Altimmune stock price forecast: brace for more ALT volatility

Altimmune (NASDAQ: ALT) stock price continued its short squeeze this week, soaring to a high of $14.52, its highest point since February 6th last year. The company's stock surged by more than 580% fro...

7 weeks ago - Invezz

Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK--(BUSINESS WIRE)---- $ALT #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Altimmune, Inc. (“Altimmune” or “...

7 weeks ago - Business Wire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

NEW YORK , Feb. 16, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Altimmune, Inc. ...

2 months ago - PRNewsWire

ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT

NEW YORK--(BUSINESS WIRE)---- $ALT #ALT--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Altimmune, Inc. ...

2 months ago - Business Wire

Altimmune stock tanks on report, should you buy the dip?

Altimmune (NASDAQ: ALT) share price experienced a significant decline on Tuesday following a report by Kerrisdale Capital, in which the investment firm disclosed a short position in the company's shar...

2 months ago - Invezz

Altimmune shares slide after Kerrisdale Capital takes short position

Shares of obesity drug developer Altimmune fell 10% to $9.36 on Tuesday, after Kerrisdale Capital took a short position on the company's stock.

2 months ago - Reuters

Up for 8 straight weeks, is Altimmune (ALT) stock a good buy?

The Altimmune (NASDAQ: ALT) stock price has been in a strong uptrend in the past few months. It bottomed at $2.07 in October, and the shares have surged by over 475% to its highest level since Februar...

3 months ago - Invezz

Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024

GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract on pemvidutide in subjects with Metabolic Dy...

3 months ago - GlobeNewsWire

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

4 months ago - Market Watch

Is Altimmune (ALT) stock a good buy after the 306% jump?

Altimmune (NASDAQ: ALT) stock proce has staged a strong recovery in the past few days, making it one of the most popular companies among day traders. The shares jumped to a high of $8.63 on Thursday, ...

4 months ago - Invezz

Altimmune shares pop as analysts see obesity-drug partnership potential

Altimmune Inc. shares ALT, +1.02% gained 5% Thursday and have jumped more than 100% this week as analysts see potential for the company to find a partner for its experimental weight-loss drug.

4 months ago - Market Watch

Altimmune open to partnerships, deals with drugmakers, says CEO

Weight-loss drug developer Altimmune is open to deals and collaborations with large drugmakers as it actively looks for partners to launch and develop its experimental obesity drug, CEO Vipin Garg tol...

4 months ago - Reuters

Here's why penny stocks like GGE, NEXI, ALT, HCDI are pumping

Penny stocks like Green Giant (GGE), Neximmune (NEXI), Altimmune (ALT), and Harbor Custom Development (HCDI) were among the best-performing companies in Wall Street on Friday. All of them jumped by mo...

Other symbols: GGENEXI
4 months ago - Invezz

Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss continuing at the end of treatment Over 30% of subjects achieved 20% or more weight loss on 2.4 mg dose at...

4 months ago - GlobeNewsWire

Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update

Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH) Top-line results ...

5 months ago - GlobeNewsWire

Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023

GAITHERSBURG, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2023 financial res...

6 months ago - GlobeNewsWire

Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

GAITHERSBURG, Md., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has gra...

6 months ago - GlobeNewsWire

Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023

GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic...

6 months ago - GlobeNewsWire

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will parti...

6 months ago - GlobeNewsWire

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes

GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Louis J. Aronne, Founder and Director of the C...

7 months ago - GlobeNewsWire